Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

Table 1 Baseline characteristics of 1003 adults with diabetes

Characteristic	n (%) or mean (sd)
History of cancer	126 (12.6%)
TZD therapy	263 (26.2%)
Pioglitazone	136 (51.3%)
Rosiglitazone	128 (48.7%)
Any TZD alone	-71 (27.0%)
TZD and biguanide	-65 (24.7%)
TZD and sulfonylurea	-56 (21.3%)
TZD and biguanide and sulfonylurea	-71 (27.0%)
Gender:
Men	457 (45.6%)
Women	546 (54.4%)
Age, years	64.8 (12.0)
White ethnicity	973 (97.3%)
Glycosolated hemoglobin A1C, %	7.13 (1.3)
Insulin use	185 (18.4%)
Body mass index, kg/m²	33.81 (7.4)
Alcohol use	274 (27.4%)
Cigarette smoking	170 (16.9%)
Median annual income, $	15000–29999
Duration of diabetes, years	10.2 (10.3)
High comorbidity	495 (49.4%)
Number of prescription medications	6.7 (3.8)
Number of anti-diabetic medications	1.2 (0.9)
Physical functional status	41.2 (12.4)
Mental functional status	50.0 (10.7)

TZD, thiazolidinedione; sd, standard deviation; n, number of subjects with the characteristic.

ISSN: 1741-7015